methylphenidate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1767	113-45-1

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: methylphenidate calocain methylphenidan phenidylate methylphenidate hydrochloride concerta methylphenidate HCl

A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE. Molecular weight: 233.31 Formula: C14H19NO2 CLOGP: 2.56 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 38.33 ALOGS: -3.11 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.29 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	22 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.42 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 5, 1955	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	287.47	10.90	272	33243	56110	46596437
Product quality issue	229.06	10.90	196	33319	35452	46617095
Agitation	186.31	10.90	214	33301	55201	46597346
Anxiety	186.18	10.90	406	33109	181551	46470996
Product substitution issue	177.62	10.90	119	33396	14912	46637635
Depression	166.56	10.90	373	33142	169731	46482816
Aggression	158.31	10.90	131	33384	22613	46629934
Tachycardia	156.81	10.90	267	33248	99355	46553192
Disturbance in attention	145.19	10.90	144	33371	31416	46621131
No adverse event	137.17	10.90	145	33370	34086	46618461
Abnormal behaviour	131.59	10.90	114	33401	20944	46631603
Drug abuse	124.46	10.90	188	33327	63220	46589327
Attention deficit hyperactivity disorder	121.53	10.90	49	33466	2123	46650424
Tic	117.07	10.90	41	33474	1195	46651352
Precocious puberty	112.11	10.90	27	33488	192	46652355
Irritability	111.35	10.90	120	33395	28826	46623721
Cataplexy	107.94	10.90	38	33477	1125	46651422
Intentional overdose	107.35	10.90	178	33337	64766	46587781
Mydriasis	95.51	10.90	71	33444	10482	46642065
Rheumatoid arthritis	92.05	10.90	29	33486	240186	46412361
Suicide attempt	91.15	10.90	151	33364	54885	46597662
Application site erythema	86.22	10.90	50	33465	4854	46647693
Hallucination, auditory	85.54	10.90	67	33448	10689	46641858
Pre-existing condition improved	84.53	10.90	55	33460	6557	46645990
Psychotic disorder	78.73	10.90	89	33426	22532	46630015
Tremor	76.73	10.90	219	33296	115420	46537127
Intentional self-injury	75.60	10.90	90	33425	24076	46628471
Wrong technique in product usage process	70.36	10.90	134	33381	54288	46598259
Apathy	68.25	10.90	50	33465	7218	46645329
Product administered at inappropriate site	66.39	10.90	33	33482	2350	46650197
Therapeutic response unexpected	64.04	10.90	67	33448	15549	46636998
Overdose	63.66	10.90	189	33326	101790	46550757
Toxicity to various agents	63.29	10.90	310	33205	211456	46441091
Rapid eye movement sleep behaviour disorder	62.62	10.90	16	33499	149	46652398
Acute kidney injury	62.30	10.90	47	33468	235808	46416739
Application site irritation	62.23	10.90	29	33486	1790	46650757
Psychomotor hyperactivity	59.95	10.90	52	33463	9561	46642986
Obsessive-compulsive disorder	59.78	10.90	34	33481	3181	46649366
Diarrhoea	58.05	10.90	207	33308	559395	46093152
Insomnia	57.02	10.90	252	33263	164672	46487875
Somnambulism	55.02	10.90	38	33477	4999	46647548
Bruxism	53.68	10.90	31	33484	2986	46649561
Anaemia	53.44	10.90	63	33452	255716	46396831
Hallucination	52.65	10.90	113	33402	49838	46602709
Enuresis	50.75	10.90	26	33489	1974	46650573
Feeling abnormal	50.16	10.90	200	33315	124860	46527687
Product administration error	49.91	10.90	66	33449	19615	46632932
Educational problem	49.73	10.90	15	33500	268	46652279
Drug dependence	49.33	10.90	66	33449	19835	46632712
Dystonia	49.23	10.90	50	33465	11207	46641340
Product colour issue	48.19	10.90	18	33497	633	46651914
Sleep apnoea syndrome	46.63	10.90	68	33447	22133	46630414
Impulsive behaviour	45.25	10.90	22	33493	1493	46651054
Social anxiety disorder	45.04	10.90	15	33500	374	46652173
Muscle twitching	44.82	10.90	54	33461	14618	46637929
Growth retardation	44.81	10.90	19	33496	936	46651611
Neutropenia	43.98	10.90	24	33491	143180	46509367
Joint swelling	42.67	10.90	34	33481	166039	46486508
Somnolence	42.40	10.90	223	33292	156298	46496249
Muscle contracture	41.56	10.90	20	33495	1327	46651220
Bipolar disorder	41.11	10.90	37	33478	7140	46645407
Panic attack	41.07	10.90	61	33454	20181	46632366
Febrile neutropenia	40.79	10.90	9	33506	94618	46557929
Parasomnia	40.20	10.90	14	33501	401	46652146
Drug diversion	39.97	10.90	17	33498	844	46651703
Pulmonary malformation	38.96	10.90	10	33505	95	46652452
Splenic infarction	38.63	10.90	20	33495	1552	46650995
Application site pruritus	38.57	10.90	28	33487	3985	46648562
Headache	38.38	10.90	517	32998	477835	46174712
Contraindicated product administered	37.88	10.90	6	33509	79941	46572606
Arthralgia	37.60	10.90	135	33380	364468	46288079
Intentional product misuse	36.97	10.90	95	33420	47033	46605514
Death	36.79	10.90	121	33394	335427	46317120
Haemoglobin decreased	36.24	10.90	24	33491	128925	46523622
Affective disorder	36.15	10.90	29	33486	4786	46647761
Dyskinesia	34.66	10.90	69	33446	28856	46623691
Memory impairment	34.52	10.90	128	33387	77209	46575338
Dyspnoea	34.45	10.90	223	33292	515325	46137222
Hallucination, visual	33.62	10.90	52	33463	17821	46634726
Anger	33.58	10.90	42	33473	11810	46640737
Application site urticaria	33.54	10.90	11	33504	261	46652286
Depressed mood	33.53	10.90	74	33441	33245	46619302
Delusion of parasitosis	33.29	10.90	6	33509	6	46652541
Crying	32.32	10.90	56	33459	21085	46631462
Narcolepsy	32.14	10.90	16	33499	1143	46651404
Livedo reticularis	31.99	10.90	20	33495	2224	46650323
Exposure during pregnancy	31.95	10.90	158	33357	108054	46544493
Withdrawal syndrome	31.68	10.90	51	33464	18083	46634464
Respiratory tract malformation	31.65	10.90	8	33507	71	46652476
Feeling jittery	31.18	10.90	39	33476	10969	46641578
Sepsis	31.14	10.90	31	33484	135983	46516564
Multiple sclerosis relapse	31.08	10.90	83	33432	42042	46610505
Paranoia	30.74	10.90	38	33477	10559	46641988
Restlessness	30.72	10.90	61	33454	25463	46627084
Hyperventilation	30.17	10.90	28	33487	5619	46646928
Solar urticaria	29.95	10.90	7	33508	43	46652504
Pneumonia	29.80	10.90	154	33361	376166	46276381
Seizure	29.73	10.90	170	33345	122884	46529663
Emotional disorder	29.21	10.90	40	33475	12284	46640263
Completed suicide	29.20	10.90	192	33323	145728	46506819
Drug hypersensitivity	28.76	10.90	85	33430	243740	46408807
Heart rate increased	28.67	10.90	118	33397	74673	46577874
Lung cyst	28.54	10.90	8	33507	109	46652438
Mania	28.47	10.90	37	33478	10809	46641738
Cardiac failure	28.25	10.90	11	33504	79937	46572610
Infection	27.76	10.90	33	33482	133559	46518988
Negative thoughts	27.75	10.90	13	33502	812	46651735
Thrombocytopenia	27.68	10.90	30	33485	126551	46525996
Cardiac failure congestive	27.26	10.90	16	33499	91734	46560813
Meningitis streptococcal	26.68	10.90	8	33507	140	46652407
Amphetamines positive	26.59	10.90	7	33508	74	46652473
Pancytopenia	26.48	10.90	14	33501	85044	46567503
Wound infection fungal	26.42	10.90	7	33508	76	46652471
Euphoric mood	26.42	10.90	23	33492	4249	46648298
Snoring	26.41	10.90	21	33494	3421	46649126
Optic disc haemorrhage	25.79	10.90	6	33509	36	46652511
Serotonin syndrome	25.75	10.90	55	33460	24165	46628382
Interstitial lung disease	25.67	10.90	4	33511	53945	46598602
Swelling	25.61	10.90	31	33484	124480	46528067
Post-traumatic stress disorder	25.45	10.90	22	33493	4026	46648521
Pre-eclampsia	25.37	10.90	30	33485	7964	46644583
Hypersomnia	25.05	10.90	42	33473	15397	46637150
Tachyphrenia	24.91	10.90	14	33501	1280	46651267
Renal failure	24.75	10.90	27	33488	113567	46538980
Sleep-related eating disorder	24.75	10.90	11	33504	608	46651939
Mood altered	24.69	10.90	38	33477	12969	46639578
Peripheral swelling	24.24	10.90	48	33467	158023	46494524
Multiple organ dysfunction syndrome	24.23	10.90	4	33511	51706	46600841
Lower respiratory tract infection	24.23	10.90	5	33510	55084	46597463
Migraine	24.15	10.90	107	33408	69919	46582628
Gastrointestinal haemorrhage	23.69	10.90	13	33502	77360	46575187
Maternal exposure during breast feeding	23.54	10.90	18	33497	2771	46649776
Psychiatric symptom	23.45	10.90	22	33493	4475	46648072
Tachypnoea	23.23	10.90	39	33476	14312	46638235
Product prescribing error	23.03	10.90	47	33468	20000	46632547
Eosinophilic myocarditis	22.90	10.90	9	33506	364	46652183
Drug screen negative	22.67	10.90	9	33506	374	46652173
Perinatal depression	22.58	10.90	10	33505	548	46651999
Application site rash	22.53	10.90	17	33498	2565	46649982
Axonal neuropathy	22.49	10.90	12	33503	990	46651557
Septic shock	22.11	10.90	7	33508	57886	46594661
Product taste abnormal	21.89	10.90	15	33500	1948	46650599
Glossodynia	21.78	10.90	3	33512	44370	46608177
Chronic fatigue syndrome	21.74	10.90	12	33503	1059	46651488
Weight decreased	21.65	10.90	239	33276	210610	46441937
Logorrhoea	21.63	10.90	16	33499	2343	46650204
Hyperkalaemia	21.49	10.90	5	33510	50704	46601843
Open angle glaucoma	21.48	10.90	8	33507	279	46652268
Atrial fibrillation	21.08	10.90	26	33489	103564	46548983
Sleep paralysis	20.87	10.90	9	33506	462	46652085
Renal impairment	20.67	10.90	14	33501	74358	46578189
Burnout syndrome	20.46	10.90	7	33508	190	46652357
Protrusion tongue	20.21	10.90	8	33507	330	46652217
Infusion related reaction	19.97	10.90	26	33489	101182	46551365
Abnormal sleep-related event	19.80	10.90	10	33505	737	46651810
General physical health deterioration	19.67	10.90	33	33482	115736	46536811
Treatment failure	19.32	10.90	23	33492	93064	46559483
Application site discolouration	19.22	10.90	10	33505	784	46651763
Respiratory failure	19.08	10.90	24	33491	94792	46557755
Social avoidant behaviour	19.01	10.90	16	33499	2823	46649724
Pleural effusion	18.87	10.90	19	33496	82933	46569614
Trichotillomania	18.72	10.90	6	33509	132	46652415
Compulsive lip biting	18.72	10.90	3	33512	0	46652547
Bezoar	18.62	10.90	12	33503	1407	46651140
Mood swings	18.55	10.90	38	33477	16214	46636333
Learning disorder	18.37	10.90	8	33507	421	46652126
Incorrect product administration duration	18.20	10.90	28	33487	9549	46642998
Initial insomnia	18.07	10.90	19	33496	4433	46648114
Hypotension	17.91	10.90	96	33419	232493	46420054
Application site pain	17.83	10.90	18	33497	4005	46648542
Thinking abnormal	17.69	10.90	28	33487	9786	46642761
Sensory level abnormal	17.63	10.90	6	33509	160	46652387
Leukopenia	17.52	10.90	14	33501	68329	46584218
Nystagmus	17.45	10.90	21	33494	5678	46646869
Rash	17.33	10.90	168	33347	356344	46296203
Therapeutic response changed	16.98	10.90	9	33506	733	46651814
Cyanosis	16.67	10.90	36	33479	15935	46636612
Bisexuality	16.64	10.90	3	33512	3	46652544
Antiphospholipid syndrome	16.58	10.90	12	33503	1700	46650847
Hunger	16.56	10.90	17	33498	3858	46648689
Platelet count decreased	16.54	10.90	29	33486	99995	46552552
Delusion	16.27	10.90	29	33486	11159	46641388
Consciousness fluctuating	16.13	10.90	8	33507	567	46651980
Libido decreased	16.06	10.90	14	33501	2591	46649956
Affect lability	16.02	10.90	24	33491	7996	46644551
Systemic lupus erythematosus	15.91	10.90	14	33501	65166	46587381
Product complaint	15.88	10.90	30	33485	12071	46640476
Nightmare	15.73	10.90	36	33479	16562	46635985
Psoriasis	15.70	10.90	20	33495	78584	46573963
Body temperature increased	15.41	10.90	46	33469	24815	46627732
Vasospasm	15.37	10.90	8	33507	628	46651919
Hyponatraemia	15.33	10.90	31	33484	101301	46551246
Cough	15.10	10.90	100	33415	230149	46422398
Substance use	15.08	10.90	7	33508	428	46652119
Lactic acidosis	15.07	10.90	3	33512	33906	46618641
C-reactive protein increased	15.02	10.90	12	33503	58578	46593969
Mobility decreased	14.81	10.90	13	33502	60581	46591966
Hepatic failure	14.76	10.90	3	33512	33413	46619134
Raynaud's phenomenon	14.65	10.90	10	33505	1290	46651257
Seizure like phenomena	14.52	10.90	9	33506	986	46651561
Arthropathy	14.51	10.90	24	33491	84676	46567871
Rhabdomyolysis	14.42	10.90	6	33509	41903	46610644
Blister	14.40	10.90	7	33508	44624	46607923
Mucosal inflammation	14.38	10.90	5	33510	38971	46613576
Pyrexia	14.28	10.90	171	33344	348631	46303916
Palpitations	14.25	10.90	117	33398	95142	46557405
International normalised ratio increased	14.17	10.90	8	33507	46875	46605672
Polycystic ovaries	14.09	10.90	10	33505	1374	46651173
Decreased appetite	14.04	10.90	206	33309	193630	46458917
Rectal haemorrhage	13.95	10.90	5	33510	38250	46614297
Sedation	13.83	10.90	42	33473	22868	46629679
Distractibility	13.82	10.90	6	33509	313	46652234
Acne	13.45	10.90	38	33477	19881	46632666
Phobia	13.41	10.90	6	33509	337	46652210
Regressive behaviour	13.39	10.90	4	33511	69	46652478
Illness	13.27	10.90	28	33487	12196	46640351
Brain death	13.19	10.90	13	33502	2810	46649737
Cleft lip and palate	13.07	10.90	6	33509	358	46652189
Coronary artery disease	13.03	10.90	4	33511	33748	46618799
Foot fracture	12.87	10.90	37	33478	19545	46633002
Herpes zoster	12.81	10.90	18	33497	67854	46584693
Formication	12.81	10.90	15	33500	3941	46648606
Oculogyric crisis	12.76	10.90	9	33506	1224	46651323
Gastric banding	12.57	10.90	4	33511	86	46652461
Malignant neoplasm progression	12.48	10.90	17	33498	64909	46587638
Abdominal discomfort	12.41	10.90	61	33454	151104	46501443
Hangover	12.36	10.90	9	33506	1286	46651261
Cerebral artery occlusion	12.35	10.90	8	33507	946	46651601
Diplopia	12.12	10.90	36	33479	19369	46633178
Acute respiratory failure	12.10	10.90	3	33512	29135	46623412
Eating disorder	11.96	10.90	30	33485	14624	46637923
Tongue biting	11.94	10.90	9	33506	1355	46651192
Drug tolerance	11.77	10.90	13	33502	3205	46649342
Grimacing	11.77	10.90	6	33509	451	46652096
Petit mal epilepsy	11.77	10.90	13	33502	3207	46649340
Drug abuser	11.72	10.90	13	33502	3220	46649327
Drug intolerance	11.70	10.90	60	33455	146989	46505558
Drug use disorder	11.69	10.90	12	33503	2723	46649824
Hypoxia	11.64	10.90	12	33503	51826	46600721
Femur fracture	11.64	10.90	6	33509	36991	46615556
Mental disorder	11.62	10.90	39	33476	22386	46630161
Schizoaffective disorder bipolar type	11.57	10.90	4	33511	112	46652435
Horner's syndrome	11.55	10.90	3	33512	30	46652517
Sleep disorder	11.51	10.90	65	33450	46730	46605817
Hallucinations, mixed	11.48	10.90	14	33501	3835	46648712
Treatment noncompliance	11.46	10.90	47	33468	29684	46622863
Hyperacusis	11.45	10.90	10	33505	1854	46650693
Nephrogenic diabetes insipidus	11.38	10.90	7	33508	756	46651791
Radius fracture	11.37	10.90	13	33502	3329	46649218
Tonic convulsion	11.28	10.90	8	33507	1098	46651449
White blood cell count decreased	11.23	10.90	42	33473	112189	46540358
Loss of consciousness	11.23	10.90	123	33392	108115	46544432
Balance disorder	11.17	10.90	82	33433	64439	46588108
Diaphragmalgia	11.07	10.90	4	33511	128	46652419
Infected cyst	10.97	10.90	7	33508	807	46651740
Nervousness	10.96	10.90	45	33470	28430	46624117

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product quality issue	857.48	13.28	429	35732	18345	29897972
No adverse event	637.06	13.28	343	35818	17076	29899241
Aggression	614.33	13.28	440	35721	36467	29879850
Tic	515.43	13.28	161	36000	1871	29914446
Agitation	406.60	13.28	408	35753	53665	29862652
Abnormal behaviour	404.43	13.28	296	35865	25327	29890990
Suicidal ideation	336.76	13.28	307	35854	35807	29880510
Product substitution issue	318.24	13.28	180	35981	9855	29906462
Wrong technique in product usage process	312.49	13.28	276	35885	30879	29885438
Irritability	305.56	13.28	240	35921	22810	29893507
Application site erythema	301.19	13.28	111	36050	2192	29914125
Psychomotor hyperactivity	292.22	13.28	159	36002	8065	29908252
Attention deficit hyperactivity disorder	276.30	13.28	98	36063	1726	29914591
Growth retardation	219.91	13.28	80	36081	1520	29914797
Psychotic disorder	212.44	13.28	189	35972	21326	29894991
Disturbance in attention	209.82	13.28	190	35971	21939	29894378
Dyskinesia	204.14	13.28	186	35975	21648	29894669
Product administration error	199.79	13.28	154	36007	14223	29902094
Product administered at inappropriate site	196.23	13.28	74	36087	1561	29914756
Acute kidney injury	195.01	13.28	46	36115	273796	29642521
Crying	192.48	13.28	106	36055	5503	29910814
Anxiety	179.94	13.28	359	35802	89512	29826805
Application site irritation	165.98	13.28	53	36108	664	29915653
Application site pruritus	163.82	13.28	62	36099	1321	29914996
Dystonia	157.00	13.28	114	36047	9613	29906704
Suicide attempt	150.65	13.28	203	35958	36494	29879823
Tachycardia	146.84	13.28	294	35867	73445	29842872
Pneumonia	146.65	13.28	114	36047	334192	29582125
Incorrect product administration duration	142.55	13.28	77	36084	3845	29912472
Insomnia	142.28	13.28	334	35827	93002	29823315
Death	134.99	13.28	140	36021	357143	29559174
Depression	134.98	13.28	321	35840	90116	29826201
Choreoathetosis	132.76	13.28	48	36113	895	29915422
Educational problem	132.31	13.28	37	36124	282	29916035
Disturbance in social behaviour	128.80	13.28	53	36108	1418	29914899
Impulsive behaviour	126.63	13.28	57	36104	1908	29914409
Anger	126.57	13.28	106	36055	11014	29905303
Intentional product misuse	124.70	13.28	180	35981	34487	29881830
Drug ineffective	116.84	13.28	755	35406	339632	29576685
Hallucination, visual	105.39	13.28	113	36048	16000	29900317
Anaemia	104.29	13.28	61	36100	207931	29708386
Intentional overdose	101.88	13.28	181	35980	41300	29875017
Withdrawal syndrome	97.67	13.28	92	36069	11158	29905159
Trismus	96.03	13.28	50	36111	2315	29914002
Mydriasis	94.61	13.28	70	36091	6073	29910244
Oppositional defiant disorder	94.22	13.28	30	36131	372	29915945
Priapism	91.46	13.28	62	36099	4681	29911636
Palpitations	89.62	13.28	152	36009	33421	29882896
Coronary artery dissection	89.40	13.28	24	36137	154	29916163
Drug diversion	87.04	13.28	35	36126	881	29915436
Product prescribing error	86.72	13.28	104	36057	16629	29899688
Drug dependence	86.12	13.28	117	36044	21178	29895139
Product complaint	84.60	13.28	64	36097	5742	29910575
Diarrhoea	83.80	13.28	174	35987	333929	29582388
Hallucination, auditory	82.97	13.28	79	36082	9710	29906607
Emotional disorder	82.87	13.28	60	36101	5034	29911283
Therapeutic product effect decreased	82.09	13.28	135	36026	28941	29887376
Hallucination, tactile	81.81	13.28	25	36136	268	29916049
Hypotension	80.81	13.28	74	36087	200491	29715826
Somnolence	79.33	13.28	277	35884	96486	29819831
Depressed mood	78.83	13.28	100	36061	16929	29899388
Overdose	78.50	13.28	252	35909	84085	29832232
Hallucination	78.40	13.28	179	35982	48880	29867437
Homicidal ideation	77.55	13.28	44	36117	2419	29913898
Bruxism	76.84	13.28	36	36125	1323	29914994
Dyspnoea	76.66	13.28	182	35979	333113	29583204
Sleep disorder	76.42	13.28	119	36042	24360	29891957
Precocious puberty	75.96	13.28	19	36142	88	29916229
Sepsis	74.64	13.28	42	36119	146353	29769964
Trichotillomania	73.75	13.28	17	36144	51	29916266
Restlessness	70.74	13.28	110	36051	22489	29893828
Application site rash	69.64	13.28	29	36132	800	29915517
Renal failure	68.66	13.28	35	36126	128931	29787386
Febrile neutropenia	68.09	13.28	22	36139	106671	29809646
Gastrointestinal haemorrhage	67.76	13.28	10	36151	83436	29832881
Logorrhoea	67.74	13.28	38	36123	2044	29914273
Paranoia	67.58	13.28	72	36089	10116	29906201
Mood altered	66.93	13.28	65	36096	8185	29908132
Mania	64.84	13.28	67	36094	9087	29907230
Decreased eye contact	64.46	13.28	23	36138	412	29915905
Cardiac failure congestive	62.24	13.28	13	36148	84394	29831923
Affect lability	61.93	13.28	43	36118	3375	29912942
Serotonin syndrome	61.54	13.28	91	36070	17800	29898517
Intentional self-injury	60.33	13.28	78	36083	13454	29902863
Haemoglobin decreased	59.19	13.28	32	36129	114066	29802251
Toxicity to various agents	59.18	13.28	391	35770	176792	29739525
Drug use disorder	59.17	13.28	41	36120	3207	29913110
Euphoric mood	57.49	13.28	45	36116	4245	29912072
Decreased appetite	57.00	13.28	342	35819	149568	29766749
Obsessive-compulsive disorder	56.72	13.28	44	36117	4097	29912220
Renal impairment	56.16	13.28	16	36145	84168	29832149
Apathy	56.08	13.28	52	36109	6180	29910137
Headache	55.94	13.28	394	35767	181912	29734405
Application site pain	55.87	13.28	31	36130	1632	29914685
Product administered to patient of inappropriate age	55.71	13.28	36	36125	2507	29913810
Feeling abnormal	54.97	13.28	172	35989	56584	29859733
Interstitial lung disease	54.36	13.28	5	36156	60192	29856125
Pyrexia	54.13	13.28	179	35982	294310	29622007
General physical health deterioration	53.36	13.28	27	36134	99917	29816400
Speech disorder	52.65	13.28	101	36060	24411	29891906
Thrombocytopenia	51.16	13.28	54	36107	136990	29779327
Autism spectrum disorder	50.91	13.28	27	36134	1298	29915019
Multiple organ dysfunction syndrome	50.63	13.28	8	36153	63479	29852838
Pancytopenia	48.45	13.28	21	36140	85031	29831286
Social avoidant behaviour	47.20	13.28	34	36127	2829	29913488
Formication	46.97	13.28	28	36133	1689	29914628
Blood creatinine increased	46.84	13.28	26	36135	91349	29824968
Enuresis	46.13	13.28	28	36133	1746	29914571
Application site urticaria	45.97	13.28	12	36149	68	29916249
Platelet count decreased	45.29	13.28	37	36124	106092	29810225
Gynaecomastia	45.06	13.28	53	36108	8298	29908019
Oromandibular dystonia	44.99	13.28	18	36143	447	29915870
Keratoconus	44.70	13.28	11	36150	47	29916270
Torticollis	44.43	13.28	23	36138	1052	29915265
Product taste abnormal	43.58	13.28	23	36138	1095	29915222
Respiratory failure	43.05	13.28	35	36126	100607	29815710
Therapeutic response unexpected	42.34	13.28	53	36108	8850	29907467
Product use issue	42.31	13.28	137	36024	45879	29870438
Alice in wonderland syndrome	41.96	13.28	9	36152	17	29916300
Hyperkalaemia	41.41	13.28	14	36147	65996	29850321
Drug abuse	41.12	13.28	202	35959	81870	29834447
Mood swings	40.49	13.28	48	36113	7578	29908739
Neutropenia	40.23	13.28	58	36103	128482	29787835
Dermatillomania	40.10	13.28	9	36152	23	29916294
Raynaud's phenomenon	40.10	13.28	15	36146	309	29916008
Hallucinations, mixed	39.82	13.28	29	36132	2454	29913863
Increased appetite	39.57	13.28	41	36120	5576	29910741
Drug screen negative	39.28	13.28	14	36147	250	29916067
Extrapyramidal disorder	37.65	13.28	55	36106	10638	29905679
Cardiac failure	36.94	13.28	28	36133	83390	29832927
Excessive eye blinking	36.17	13.28	13	36148	238	29916079
Product colour issue	35.61	13.28	15	36146	426	29915891
Product adhesion issue	35.23	13.28	22	36139	1443	29914874
Oedema peripheral	34.87	13.28	46	36115	105786	29810531
Atrial fibrillation	34.61	13.28	48	36113	108076	29808241
Heart rate increased	34.44	13.28	114	36047	38607	29877710
Off label use	34.35	13.28	455	35706	248835	29667482
Ventricular parasystole	34.32	13.28	6	36155	0	29916317
Onychophagia	34.22	13.28	8	36153	26	29916291
Suicidal behaviour	34.14	13.28	21	36140	1341	29914976
Phobia	34.00	13.28	10	36151	93	29916224
Incorrect dose administered	33.44	13.28	99	36062	31587	29884730
Generalised tonic-clonic seizure	33.06	13.28	73	36088	19478	29896839
Septic shock	32.73	13.28	18	36143	63589	29852728
White blood cell count decreased	32.52	13.28	32	36129	83915	29832402
Hypertension	32.43	13.28	254	35907	121100	29795217
Plasma cell myeloma	32.39	13.28	12	36149	53450	29862867
Coordination abnormal	32.39	13.28	42	36119	7263	29909054
Muscle contracture	32.23	13.28	19	36142	1123	29915194
Screaming	32.04	13.28	20	36141	1311	29915006
Affective disorder	32.04	13.28	28	36133	3080	29913237
Sleep apnoea syndrome	32.03	13.28	66	36095	16791	29899526
Drug tolerance	31.86	13.28	24	36137	2138	29914179
Treatment noncompliance	31.66	13.28	84	36077	25169	29891148
Rheumatoid arthritis	31.07	13.28	6	36155	41191	29875126
Tourette's disorder	30.96	13.28	9	36152	80	29916237
Asthenia	30.19	13.28	151	36010	221139	29695178
Peripheral coldness	29.42	13.28	38	36123	6545	29909772
Bipolar disorder	29.23	13.28	29	36132	3747	29912570
Rebound effect	29.13	13.28	20	36141	1541	29914776
Peripheral swelling	29.01	13.28	19	36142	61055	29855262
Tardive dyskinesia	28.80	13.28	33	36128	5024	29911293
Tremor	28.61	13.28	172	35989	75191	29841126
Sympathomimetic effect	28.60	13.28	5	36156	0	29916317
Hyperkinesia	28.10	13.28	22	36139	2076	29914241
Gilbert's syndrome	27.88	13.28	7	36154	33	29916284
Delusion	27.73	13.28	51	36110	11938	29904379
Joint swelling	27.67	13.28	11	36150	46935	29869382
Arthralgia	27.37	13.28	79	36082	135712	29780605
Metabolic acidosis	27.13	13.28	6	36155	37455	29878862
Nervousness	27.08	13.28	50	36111	11738	29904579
Cough	26.88	13.28	71	36090	125571	29790746
Pain	26.37	13.28	113	36048	172528	29743789
Application site erosion	26.24	13.28	8	36153	85	29916232
Melaena	26.05	13.28	4	36157	32433	29883884
Chronic kidney disease	25.57	13.28	7	36154	37831	29878486
Dysphemia	25.36	13.28	18	36143	1463	29914854
International normalised ratio increased	25.30	13.28	13	36148	47726	29868591
Change in sustained attention	25.14	13.28	5	36156	5	29916312
Completed suicide	24.80	13.28	205	35956	99287	29817030
Mental disorder	24.78	13.28	52	36109	13397	29902920
Delayed puberty	24.78	13.28	9	36152	170	29916147
Infection	24.63	13.28	35	36126	78039	29838278
Cataplexy	24.61	13.28	11	36150	362	29915955
Polydipsia psychogenic	24.17	13.28	8	36153	113	29916204
Cerebral congestion	24.13	13.28	6	36155	27	29916290
Multiple cardiac defects	23.62	13.28	7	36154	67	29916250
Somnambulism	23.62	13.28	24	36137	3190	29913127
Pleural effusion	23.57	13.28	33	36128	74033	29842284
Hyperhidrosis	23.50	13.28	150	36011	66940	29849377
Product dispensing error	23.26	13.28	32	36129	5857	29910460
Fall	23.16	13.28	127	36034	181745	29734572
Weight gain poor	23.02	13.28	14	36147	876	29915441
Coronary artery disease	22.89	13.28	16	36145	49696	29866621
Distractibility	22.78	13.28	10	36151	315	29916002
Blood urea increased	22.78	13.28	5	36156	31376	29884941
Oxygen saturation decreased	22.77	13.28	12	36149	43428	29872889
Illusion	22.26	13.28	13	36148	755	29915562
Erythema	22.25	13.28	37	36124	77414	29838903
Malignant neoplasm progression	22.22	13.28	33	36128	72254	29844063
Colitis	22.19	13.28	5	36156	30815	29885502
Dehydration	21.98	13.28	76	36085	123463	29792854
Drug withdrawal syndrome	21.96	13.28	63	36098	19746	29896571
Tongue spasm	21.90	13.28	6	36155	42	29916275
Self-injurious ideation	21.82	13.28	17	36144	1592	29914725
Infusion related reaction	21.57	13.28	11	36150	40553	29875764
Panic attack	21.44	13.28	38	36123	8643	29907674
Hyponatraemia	21.32	13.28	30	36131	67172	29849145
Liver disorder	21.04	13.28	5	36156	29717	29886600
School refusal	21.00	13.28	5	36156	18	29916299
Sudden death	20.92	13.28	53	36108	15439	29900878
Application site dryness	20.88	13.28	6	36155	51	29916266
Substance abuse	20.27	13.28	33	36128	7007	29909310
Petit mal epilepsy	19.98	13.28	20	36141	2611	29913706
Seizure	19.96	13.28	194	35967	98281	29818036
Neuropathy peripheral	19.93	13.28	34	36127	70441	29845876
Application site scab	19.83	13.28	6	36155	62	29916255
Strabismus	19.72	13.28	14	36147	1138	29915179
Performance status decreased	19.52	13.28	24	36137	3933	29912384
Drooling	19.51	13.28	21	36140	2984	29913333
Pain in extremity	19.48	13.28	68	36093	110153	29806164
Abdominal distension	19.40	13.28	16	36145	45693	29870624
Regressive behaviour	19.35	13.28	5	36156	27	29916290
Scoliosis	19.31	13.28	16	36145	1636	29914681
Myocardial infarction	19.31	13.28	82	36079	125543	29790774
Muscle twitching	19.25	13.28	35	36126	8120	29908197
Panic reaction	19.22	13.28	15	36146	1408	29914909
Incorrect route of product administration	18.85	13.28	42	36119	11273	29905044
Disease progression	18.74	13.28	43	36118	79831	29836486
Migraine	18.39	13.28	45	36116	12829	29903488
Chorea	18.08	13.28	13	36148	1078	29915239
Cholestasis	18.06	13.28	4	36157	24946	29891371
Suspiciousness	18.05	13.28	9	36152	380	29915937
Negativism	18.03	13.28	9	36152	381	29915936
Drug reaction with eosinophilia and systemic symptoms	17.93	13.28	6	36155	28482	29887835
Product dose omission issue	17.83	13.28	179	35982	91452	29824865
Insulin resistance	17.58	13.28	10	36151	552	29915765
C-reactive protein increased	17.50	13.28	16	36145	43457	29872860
Hepatic function abnormal	17.41	13.28	15	36146	41930	29874387
Accidental exposure to product	17.36	13.28	38	36123	10077	29906240
Erection increased	17.36	13.28	10	36151	566	29915751
Idiopathic intracranial hypertension	17.32	13.28	10	36151	568	29915749
Parasomnia	17.28	13.28	8	36153	286	29916031
Encopresis	17.25	13.28	5	36156	44	29916273
Blood creatine phosphokinase increased	17.22	13.28	101	36060	43747	29872570
Limb girth decreased	17.16	13.28	3	36158	0	29916317
Adhesive tape use	17.16	13.28	3	36158	0	29916317
Cardiac contusion	17.16	13.28	3	36158	0	29916317
Psychopathic personality	17.16	13.28	3	36158	0	29916317
Testicular failure	17.15	13.28	5	36156	45	29916272
Poor quality product administered	17.13	13.28	15	36146	1654	29914663
Haematoma	17.01	13.28	4	36157	23949	29892368
Accommodation disorder	16.98	13.28	7	36154	188	29916129
Dermo-hypodermitis	16.97	13.28	8	36153	298	29916019
Device difficult to use	16.93	13.28	10	36151	593	29915724
Pneumonitis	16.90	13.28	6	36155	27448	29888869
Weight increased	16.89	13.28	151	36010	74762	29841555
Frustration tolerance decreased	16.88	13.28	16	36145	1954	29914363
Blood thyroid stimulating hormone increased	16.88	13.28	19	36142	2837	29913480
Vision blurred	16.86	13.28	97	36064	41719	29874598
Physical assault	16.85	13.28	13	36148	1200	29915117
Wolff-Parkinson-White syndrome	16.68	13.28	7	36154	197	29916120
Pre-existing condition improved	16.67	13.28	16	36145	1985	29914332
Neutrophil count decreased	16.64	13.28	16	36145	42438	29873879
Mucosal inflammation	16.62	13.28	8	36153	30486	29885831
Rash	16.56	13.28	150	36011	191739	29724578
Constipation	16.55	13.28	75	36086	112831	29803486
Hypocalcaemia	16.36	13.28	3	36158	21373	29894944
Chronic obstructive pulmonary disease	16.28	13.28	19	36142	46107	29870210
Application site ulcer	16.27	13.28	4	36157	17	29916300
Libido increased	16.19	13.28	11	36150	833	29915484
Sedation	16.18	13.28	50	36111	16323	29899994
Lower respiratory tract infection	16.17	13.28	6	36155	26708	29889609
Pericardial effusion	16.11	13.28	3	36158	21141	29895176
Stress cardiomyopathy	16.06	13.28	14	36147	1535	29914782
Application site discolouration	15.99	13.28	7	36154	219	29916098
Ascites	15.96	13.28	12	36149	35909	29880408
Bone marrow failure	15.95	13.28	8	36153	29777	29886540
Accidental exposure to product by child	15.95	13.28	14	36147	1549	29914768
Sydenham's chorea	15.91	13.28	4	36157	19	29916298
Vasospasm	15.84	13.28	8	36153	347	29915970
Acute psychosis	15.63	13.28	15	36146	1861	29914456
Oculogyric crisis	15.42	13.28	13	36148	1362	29914955
Hypokalaemia	15.34	13.28	23	36138	50169	29866148
Disinhibition	15.09	13.28	15	36146	1942	29914375
Anorexia nervosa	15.09	13.28	3	36158	3	29916314
Drug resistance	15.04	13.28	3	36158	20130	29896187
Opisthotonus	14.98	13.28	8	36153	390	29915927
Hypoglycaemia	14.97	13.28	24	36137	50957	29865360
Hepatocellular injury	14.95	13.28	6	36155	25465	29890852
Blood growth hormone decreased	14.85	13.28	4	36157	26	29916291
Eye movement disorder	14.83	13.28	21	36140	3947	29912370
Meningitis staphylococcal	14.77	13.28	5	36156	76	29916241
Urinary tract infection	14.71	13.28	43	36118	73616	29842701
Social anxiety disorder	14.67	13.28	7	36154	268	29916049
Acute respiratory distress syndrome	14.67	13.28	5	36156	23467	29892850
Inappropriate affect	14.66	13.28	9	36152	573	29915744
Productive cough	14.66	13.28	9	36152	29944	29886373
Hypoxia	14.55	13.28	22	36139	47832	29868485
Poor quality sleep	14.52	13.28	29	36132	7212	29909105
Prescribed overdose	14.51	13.28	32	36129	8529	29907788
Psoriasis	14.47	13.28	18	36143	42488	29873829
Amnesia	14.47	13.28	63	36098	24258	29892059
Product residue present	14.45	13.28	17	36144	2661	29913656
Hyperacusis	14.32	13.28	9	36152	597	29915720
Thrombosis	14.26	13.28	18	36143	42213	29874104
Stubbornness	14.24	13.28	4	36157	31	29916286
Ataxia	14.23	13.28	38	36123	11424	29904893
Epiphyses delayed fusion	14.23	13.28	3	36158	5	29916312
Pressure of speech	14.20	13.28	8	36153	434	29915883
Gastrooesophageal reflux disease	14.05	13.28	11	36150	32244	29884073
Defect conduction intraventricular	14	13.28	6	36155	178	29916139
Nightmare	13.96	13.28	39	36122	12037	29904280
Reading disorder	13.94	13.28	7	36154	300	29916017
Pulmonary embolism	13.93	13.28	48	36113	78087	29838230
Dysphoria	13.92	13.28	15	36146	2133	29914184
Electrocardiogram T wave inversion	13.89	13.28	15	36146	2139	29914178
Schizotypal personality disorder	13.87	13.28	3	36158	6	29916311
Personality change	13.84	13.28	22	36139	4578	29911739
Narcolepsy	13.83	13.28	8	36153	456	29915861
Compulsions	13.75	13.28	6	36155	186	29916131
Stomatitis	13.54	13.28	15	36146	37264	29879053
Therapeutic product effect delayed	13.51	13.28	11	36150	1098	29915219
Osteonecrosis of jaw	13.44	13.28	3	36158	18615	29897702
Substance-induced psychotic disorder	13.42	13.28	12	36149	1360	29914957
Urinary incontinence	13.41	13.28	48	36113	16892	29899425
Lung disorder	13.37	13.28	11	36150	31458	29884859
Therapeutic product effect increased	13.35	13.28	9	36152	673	29915644

Pharmacologic Action:

Source	Code	Description
ATC	N06BA04	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
FDA PE	N0000175729	Central Nervous System Stimulation
FDA EPC	N0000175739	Central Nervous System Stimulant
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
CHEBI has role	CHEBI:35337	analeptic drug
CHEBI has role	CHEBI:35471	psychopharmaceuticals
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:37962	adrenergic neuron agents
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Narcolepsy	indication	60380001	DOID:8986
Attention deficit hyperactivity disorder	indication	406506008
Depressive disorder	off-label use	35489007
Cognitive Impairment following Traumatic Brain Injury	off-label use
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Dependent drug abuse	contraindication	6525002
Alcoholism	contraindication	7200002
Sinus tachycardia	contraindication	11092001
Bipolar disorder	contraindication	13746004	DOID:3312
Mood swings	contraindication	18963009
Lowered convulsive threshold	contraindication	19260006
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Short bowel syndrome	contraindication	26629001	DOID:10605
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Tension	contraindication	53489000
Anorexia nervosa	contraindication	56882008	DOID:8689
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Severe anxiety (panic)	contraindication	80583007
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Cardiomyopathy	contraindication	85898001	DOID:0050700
Thyrotoxicosis	contraindication	90739004	DOID:7997
Blurring of visual image	contraindication	111516008
Gastrointestinal obstruction	contraindication	126765001
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Esophageal dysmotility	contraindication	266434009	DOID:9192
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Visual impairment	contraindication	397540003
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000
Life-Threatening Cardiac Arrhythmias	contraindication
Uncontrolled Epilepsy	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.68	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	JORNULLY PM	IRONSHORE PHARMS	N209311	Aug. 8, 2018	RX	CAPSULE, EXTENDED RELEASE	ORAL	Aug. 8, 2021	NEW PRODUCT
20MG	JORNULLY PM	IRONSHORE PHARMS	N209311	Aug. 8, 2018	RX	CAPSULE, EXTENDED RELEASE	ORAL	Aug. 8, 2021	NEW PRODUCT
40MG	JORNULLY PM	IRONSHORE PHARMS	N209311	Aug. 8, 2018	RX	CAPSULE, EXTENDED RELEASE	ORAL	Aug. 8, 2021	NEW PRODUCT
60MG	JORNULLY PM	IRONSHORE PHARMS	N209311	Aug. 8, 2018	RX	CAPSULE, EXTENDED RELEASE	ORAL	Aug. 8, 2021	NEW PRODUCT
80MG	JORNULLY PM	IRONSHORE PHARMS	N209311	Aug. 8, 2018	RX	CAPSULE, EXTENDED RELEASE	ORAL	Aug. 8, 2021	NEW PRODUCT
25MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT
35MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT
45MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT
55MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT
70MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT
85MG	ADHANSIA XR	PURDUE PHARMA LP	N212038	Feb. 27, 2019	RX	CAPSULE, EXTENDED RELEASE	ORAL	Feb. 27, 2022	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	6.18		CHEMBL	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	Ki	6.96		CHEMBL	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.25		PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.07		PDSP
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	4.19		CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.61		PDSP
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	7.08		CHEMBL

External reference:

ID	Source
4019832	VUID
N0000147920	NUI
D01296	KEGG_DRUG
20748-11-2	SECONDARY_CAS_RN
4018198	VANDF
4019832	VANDF
C0939301	UMLSCUI
CHEBI:31836	CHEBI
CHEMBL796	ChEMBL_ID
CHEMBL1722	ChEMBL_ID
D008774	MESH_DESCRIPTOR_UI
DB00422	DRUGBANK_ID
4158	PUBCHEM_CID
7236	IUPHAR_LIGAND_ID
485	INN_ID
207ZZ9QZ49	UNII
203188	RXNORM
1038	MMSL
32827	MMSL
37867	MMSL
5092	MMSL
d00900	MMSL
001540	NDDF
004619	NDDF
18548003	SNOMEDCT_US
373337007	SNOMEDCT_US
42163009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ritalin LA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0370	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	NDA	31 sections
Ritalin LA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0371	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	NDA	31 sections
Ritalin LA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0372	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	NDA	31 sections
Ritalin LA	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0424	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	NDA	31 sections
Ritalin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0439	TABLET	5 mg	ORAL	NDA	30 sections
Ritalin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0440	TABLET	10 mg	ORAL	NDA	30 sections
Ritalin	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0441	TABLET	20 mg	ORAL	NDA	30 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5292	CAPSULE, EXTENDED RELEASE	50 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5293	CAPSULE, EXTENDED RELEASE	60 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5295	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5296	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5297	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(CD)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5298	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	ANDA	26 sections
Methylphenidate Hydrochloride(LA)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5346	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	ANDA	29 sections
Methylphenidate Hydrochloride(LA)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5347	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	ANDA	29 sections
Methylphenidate Hydrochloride(LA)	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5348	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	ANDA	29 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1736	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	ANDA	15 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1737	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	ANDA	15 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1738	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	ANDA	15 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1739	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	ANDA	15 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1740	CAPSULE, EXTENDED RELEASE	50 mg	ORAL	ANDA	15 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1741	CAPSULE, EXTENDED RELEASE	60 mg	ORAL	ANDA	15 sections
METHYLPHENIDATE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1800	TABLET	5 mg	ORAL	ANDA	28 sections
METHYLPHENIDATE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1801	TABLET	10 mg	ORAL	ANDA	28 sections
METHYLPHENIDATE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1802	TABLET	20 mg	ORAL	ANDA	28 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0896	SOLUTION	5 mg	ORAL	ANDA	21 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1792	SOLUTION	10 mg	ORAL	ANDA	21 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8155	TABLET, FILM COATED, EXTENDED RELEASE	18 mg	ORAL	ANDA	33 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8156	TABLET, FILM COATED, EXTENDED RELEASE	27 mg	ORAL	ANDA	33 sections
Methylphenidate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8157	TABLET, FILM COATED, EXTENDED RELEASE	36 mg	ORAL	ANDA	33 sections